Who are Herceptin Hylecta®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trastuzumab + Pertuzumab, trastuzumab (H), Pertuzumab + trastuzumab, Pertuzumab and Trastuzumab, Pertuzumab and Trastuzumab FDC SC, FDC of Pertuzumab and Trastuzumab SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/herceptin-hylecta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Herceptin Hylecta® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Herceptin Hylecta® (Herceptin Hylecta®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted monoclonal antibody. Area: Oncology.

marketed HER2-targeted monoclonal antibody HER2 (human epidermal growth factor receptor 2) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Herceptin Hylecta® (Herceptin Hylecta®) — Biocon Biologics UK PLC. Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Herceptin Hylecta® TARGET	Herceptin Hylecta®	Biocon Biologics UK PLC	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Trastuzumab + Pertuzumab	Trastuzumab + Pertuzumab	Massachusetts General Hospital	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
trastuzumab (H)	trastuzumab (H)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab	Pertuzumab and Trastuzumab	QuantumLeap Healthcare Collaborative	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab FDC SC	Pertuzumab and Trastuzumab FDC SC	Hoffmann-La Roche	phase 3	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
FDC of Pertuzumab and Trastuzumab SC	FDC of Pertuzumab and Trastuzumab SC	Hoffmann-La Roche	phase 3	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted monoclonal antibody class)

Spanish Breast Cancer Research Group · 3 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 1 drug in this class
Biocon Biologics UK PLC · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class
Tanvex BioPharma USA, Inc. · 1 drug in this class
Zydus Lifesciences Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Herceptin Hylecta® — Competitive Intelligence Brief. https://druglandscape.com/ci/herceptin-hylecta. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing